Status:
COMPLETED
A Study of LY3832479 (LY-CoV016) in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bl...
Eligibility Criteria
Inclusion
- Are overtly healthy as determined by medical evaluation including medical history and physical examination
Exclusion
- Test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Pregnant women and women of childbearing potential
- Have a history or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that, in the opinion of the investigator, are capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk while taking the investigational product, or of interfering with the interpretation of data
- Have participated in a clinical study involving an investigational product, with last dose within the past 30 days or 5 half-lives (whichever is longer) prior to dosing
Key Trial Info
Start Date :
June 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04441931
Start Date
June 19 2020
End Date
October 2 2020
Last Update
December 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Inc
Daytona Beach, Florida, United States, 32117